UB Paderborn / Katalog / Suche / in CDI

1 – 23 von 23

Sortiert nach

The Circadian Clock in Cancer Development and Therapy

Progress in Molecular Biology and Translational Science, 2013, Vol.119, p.221-282

2013

Link zum Volltext

Verfügbarkeit prüfen

Circadian Dysfunction Induces Leptin Resistance in Mice

Cell metabolism, 2015-09, Vol.22 (3), p.448-459

2015

Link zum Volltext

Verfügbarkeit prüfen

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis

Cancer cell, 2016-12, Vol.30 (6), p.909-924

2016

Link zum Volltext

Verfügbarkeit prüfen

SRC-2 Is an Essential Coactivator for Orchestrating Metabolism and Circadian Rhythm

Cell reports (Cambridge), 2014-02, Vol.6 (4), p.633-645

2014

Link zum Volltext

Verfügbarkeit prüfen

Circadian gene variants in cancer

Annals of medicine (Helsinki), 2014-06, Vol.46 (4), p.208-220

2014

Link zum Volltext

Verfügbarkeit prüfen

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

International journal of cancer, 2022-06, Vol.150 (12), p.2025-2037

2022

Link zum Volltext

Verfügbarkeit prüfen

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer

Clinical cancer research, 2019-07, Vol.25 (13), p.3996-4013

2019

Link zum Volltext

Verfügbarkeit prüfen

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers

Cancer research (Chicago, Ill.), 2023-10, Vol.83 (19), p.3264

2023

Link zum Volltext

Verfügbarkeit prüfen

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

Cancer research (Chicago, Ill.), 2023-03, Vol.83 (6), p.939-955

2023

Link zum Volltext

Verfügbarkeit prüfen

Small Heterodimer Partner (NR0B2) Coordinates Nutrient Signaling and the Circadian Clock in Mice

Molecular endocrinology (Baltimore, Md.), 2016-09, Vol.30 (9), p.988-995

2016

Link zum Volltext

Verfügbarkeit prüfen

Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology

Journal of biological rhythms, 2016-10, Vol.31 (5), p.443-460

2016

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-03-09

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.PD2-05-PD2-05

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P1-P1-19-01

2022

Link zum Volltext

Verfügbarkeit prüfen

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.1067-1067

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P6-P6-04-12

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract A32: Studying circadian disruption as a novel risk factor of hepatocellular carcinoma using mouse models

Molecular cancer research, 2014-11, Vol.12 (11_Supplement), p.A32-A32

2014

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4346: TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4346-4346

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer

Cancer research (Chicago, Ill.), 2019-07, Vol.79 (13_Supplement), p.323-323

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract 3107: Identifying therapeutic vulnerabilities in HR-positive, HER2-negative advanced breast cancer patient-derived xenograft models refractory to CDK4/6 inhibition

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.3107-3107

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1798: Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1798-1798

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1774: Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.1774-1774

2022

Link zum Volltext

Verfügbarkeit prüfen

Uncertainty quantification in modeling earth surface processes: more applicable for some types of models than for others

Computers & geosciences, 2016-05, Vol.90, p.6-16

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 23 von 23

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(23)
Mit Volltextzugriff
(21)

Publikationsform

Artikel
(23)

Sprache

Englisch
(23)
Japanisch
(4)

Erscheinungsjahr

n.n

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Circadian Clock in Cancer Development and Therapy

Circadian Dysfunction Induces Leptin Resistance in Mice

Circadian Homeostasis of Liver Metabolism Suppresses Hepatocarcinogenesis

SRC-2 Is an Essential Coactivator for Orchestrating Metabolism and Circadian Rhythm

Circadian gene variants in cancer

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2− metastatic breast cancer patients compared to endocrine therapy alone in the second‐line setting: A large institutional study

Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer

Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time

Small Heterodimer Partner (NR0B2) Coordinates Nutrient Signaling and the Circadian Clock in Mice

Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology

Abstract P6-03-09: Role of IL-6 in promoting endocrine therapy and palbociclib resistance estrogen receptor positive breast cancer cells

Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers

Abstract P1-19-01: Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC)

Abstract P6-04-12: STAT3 as a therapeutic target in estrogen receptor positive breast cancer patients refractory to CDK4/6 inhibition

Abstract A32: Studying circadian disruption as a novel risk factor of hepatocellular carcinoma using mouse models

Abstract 4346: TFF1 and TFF3 predict response to CDK4/6 inhibitors in breast cancer patients

Abstract 323: Combined inhibition of STAT-3 & DNA repair in palbociclib resistant breast cancer

Abstract 3107: Identifying therapeutic vulnerabilities in HR-positive, HER2-negative advanced breast cancer patient-derived xenograft models refractory to CDK4/6 inhibition

Abstract 1798: Mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib

Abstract 1774: Circulating IL-6, an early biomarker in HR-positive, HER2-negative metastatic breast cancer patients progressing on CDK4/6 inhibitors

Uncertainty quantification in modeling earth surface processes: more applicable for some types of models than for others

Suchergebnisse filtern